Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. - Wikidata - awgldk - TriplyDB

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

http://www.wikidata.org/entity/Q33931450

about

A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma Association between the KRAS Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population.The discovery and development of sorafenib for the treatment of thyroid cancer.Loss of c-KIT expression in thyroid cancer cells.HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation.Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg.Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Higher expression level of tyrosine kinase-like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis.Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer

P2860

Q33656624-C3DDDB70-50F0-4AC0-BAE3-0B602A2DE4C6 Q36229033-D2752E2C-ADC4-4A46-B3A9-962CC6408A99 Q36263304-FA73DB53-DAC8-484F-B8FB-097B5F6C5EA7 Q36310913-483AC119-34E9-405C-830F-5C91387D8E96 Q36336147-1C8DC2E8-4177-406E-928B-34990A06DE38 Q36352337-6825F5EC-B085-4ECE-86D4-CC8284650945 Q37086109-6CB7C327-5185-4C03-B303-B6D1B5FDF368 Q37725502-B07B4E66-D322-42E1-A5BD-9FD2D7E50B4B Q39040663-9474AE6E-D881-434C-B772-823531160B2B Q40206178-ACCA4CF6-7D81-4E7B-A768-C1D1D582724F Q40640698-AC682893-0DD8-4459-BFD6-0D02B1A9FC40 Q41418283-FC934964-6661-493A-94FB-A2561A78953A Q47162063-7D9BC906-6A8F-43D3-A5F4-9949715DEA8A Q47646209-445FCE4E-E715-44E6-AE26-1A830F3D9255 Q52647717-D80DC572-8E31-4A5F-9126-29197FCE765B Q52664598-A03F5836-1F77-444A-8392-606D424BB719 Q54088641-7F6BEE45-AFCA-4A78-8090-1447C8CF3FEF Q54967888-C4E29AB7-2AD8-483F-8001-17B2977F18BD Q58796314-00E5F711-AD44-400F-8A5C-C878FD665E01 Q58856556-25411445-7438-4C39-A7B0-9B201E422FB8

P2860

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

http://www.wikidata.org/entity/Q33931450

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@ast

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@en

type

label

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@ast

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@en

prefLabel

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@ast

Concomitant RAS, RET/PTC, or B ...... f papillary thyroid carcinoma.

@en

P1433

Q33931450-74A54397-E972-4034-9BAC-2A683BACFD0A

P1476

Q33931450-221F304D-6CE9-4852-BEB8-FA1968FB126A

P2093

Q33931450-1E2A923D-A2F8-45D2-9444-4D2D7E8F0874

Q33931450-5E0A9F50-91BE-4C19-87CA-F01289EDADF1

Q33931450-714B1CF7-7E44-4601-A760-5B833B44054C

Q33931450-A409CD14-7EE3-4A65-9BBE-4047C5D6FDF0

Q33931450-D6B9B8CB-1A44-4365-A668-49447E1EB9BB

Q33931450-DE94B723-F481-405A-A13C-FC9D8790882D

Q33931450-F49229CF-42BD-4B1B-B5AB-8DDEFC9AA124

P2860

Q33931450-021E16B6-1E9F-42E4-AA8A-772D3F4A14B2

Q33931450-12477034-9A04-4E39-A8B1-FB38B291921A

Q33931450-27D56EF3-ECB9-4E9C-8436-47A7AB831B04

Q33931450-2CFF241F-A498-4E4F-90B9-B92E87C8A01B

Q33931450-311CE4B1-69B5-4BBA-ADF3-C81525095F0E

Q33931450-356C2D6D-B42A-4EDE-ADAD-EA2693B8DA59

Q33931450-364B4CC7-4B14-464B-9884-097D7052AD0E

Q33931450-3DE64DFC-30FC-4127-A732-CA13A8256EEB

Q33931450-3F72C8FA-2A88-4CAB-8D90-5BC1EBD26F12

Q33931450-4BDDC273-3026-4E0A-B5B3-34FF8A5EA758

P304

Q33931450-72061AE9-862B-457C-B634-C0F46385A79E

P31

Q33931450-20F3E152-A826-4F1B-BE57-04FF710F06D1

P356

Q33931450-AD5D9E67-F3FD-4441-B56F-6CA36351003A

P433

Q33931450-1340A566-A60D-453B-BE0A-FD467F7A93AE

P478

Q33931450-489E5CC3-2484-40D3-A4E7-4C02D08560CB

P50

Q33931450-AA5DA553-759A-4679-95B5-4EEFE4B9F2B5

P577

Q33931450-39CE2015-77BD-49E6-9ED5-13FC91B32BEF

P698

Q33931450-B663BB56-30E4-42A2-B2FD-68EC3B4F50C0

P932

Q33931450-456899D6-F224-4087-9DA2-AB9FDC366D71

P356

P1433

P1476

Concomitant RAS, RET/PTC, or B ...... of papillary thyroid carcinoma

@en

P2093

Ali S Alzahrani

http://www.w3.org/2001/XMLSchema#string

Brian F Meyer

http://www.w3.org/2001/XMLSchema#string

Dania Alkhafaji

http://www.w3.org/2001/XMLSchema#string

Essa Y Baitei

http://www.w3.org/2001/XMLSchema#string

Faisal S BinHumaid

http://www.w3.org/2001/XMLSchema#string

Minjing Zou

http://www.w3.org/2001/XMLSchema#string

Roua A Al-Rijjal

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.

High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma

P304

1256-1266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2013.0610

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24798740

http://www.w3.org/2001/XMLSchema#string

P932

4106383

http://www.w3.org/2001/XMLSchema#string